AGTC Announces Positive Three-Month Interim Results From Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).